Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913620 | 1.00 | TAAR1 (0.52) | TAAR1HTR2ACHRNB2CHRNA4NOS2 | |
| SCHEMBL9734378 | 1.00 | TAAR1 (0.52) | TAAR1HTR2ACHRNB2CHRNA4NOS2 | |
| Hydrochloric Acid SCHEMBL20746350 | 0.98 | TAAR1 (0.50) | TAAR1HTR2ACHRNB2CHRNA4NOS2 | |
| SCHEMBL2871199 | 0.88 | CHRNB2 (0.57) | TAAR1HTR2ACHRNB2CHRNA4 | |
| SCHEMBL6336591 | 0.83 | HRH1 (0.56) | TAAR1HTR2ANOS2HRH1SLC6A2 | |
| SCHEMBL6343043 | 0.81 | SLC6A4 (0.41) | TAAR1HTR2AHRH1SLC6A2SLC6A4 | |
| SCHEMBL13569341 | 0.80 | AOC3 (0.42) | TAAR1 | |
| SCHEMBL13569343 | 0.80 | AOC3 (0.42) | TAAR1 | |
| SCHEMBL18257696 | 0.80 | AOC3 (0.42) | TAAR1 | |
| SCHEMBL8269660 | 0.79 | LMNA (0.48) | TAAR1HTR2AHRH1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076456-A1 | SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF | Université de Strasbourg (FR) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123174-A1 | SIGMA-1 RECEPTOR LIGANDS AND THERAPEUTIC USES THEREOF | UNIVERSITE DE STRASBOURG (FR) | 2021-06-24 | — | — | WO | disclosed |
| US-7632972-B2 | Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIONIS (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632972-B2 | Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIONIS (US) | 2009-12-15 | — | — | US | disclosed |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-6888022-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ATHENA NEUROSCIENCES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6861558-B2 | Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | AUDIA JAMES E (US) | 2003-12-11 | — | — | US | disclosed |
| US-6476263-B1 | Compounds for inhibiting β-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | ELAN PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6211235-B1 | ALZHEIMERS DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6207710-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| US-6191166-B1 | ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052322-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | TAAR1 2561/4885HTR2A 1574/4885CHRNB2 207/4885 |
| US-20060223761-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | TAAR1 2528/4885HTR2A 1622/4885CHRNB2 175/4885 |
| US-20030229024-A1 | Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis | APP, BACE1, IAPP | TAAR1 2561/4885HTR2A 1574/4885CHRNB2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.